Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 1;99(1):175-84.
doi: 10.1093/cvr/cvt083. Epub 2013 Apr 3.

TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves

Affiliations

TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves

Michael A Hagler et al. Cardiovasc Res. .

Abstract

Aims: Myxomatous mitral valve disease (MMVD) is associated with leaflet thickening, fibrosis, matrix remodelling, and leaflet prolapse. Molecular mechanisms contributing to MMVD, however, remain poorly understood. We tested the hypothesis that increased transforming growth factor-β (TGF-β) signalling and reactive oxygen species (ROS) are major contributors to pro-fibrotic gene expression in human and mouse mitral valves.

Methods and results: Using qRT-PCR, we found that increased expression of TGF-β1 in mitral valves from humans with MMVD (n = 24) was associated with increased expression of connective tissue growth factor (CTGF) and matrix metalloproteinase 2 (MMP2). Increased levels of phospho-SMAD2/3 (western blotting) and expression of SMAD-specific E3 ubiquitin-protein ligases (SMURF) 1 and 2 (qRT-PCR) suggested that TGF-β1 signalling occurred through canonical signalling cascades. Oxidative stress (dihydroethidium staining) was increased in human MMVD tissue and associated with increases in NAD(P)H oxidase catalytic subunits (Nox) 2 and 4, occurring despite increases in superoxide dismutase 1 (SOD1). In mitral valves from SOD1-deficient mice, expression of CTGF, MMP2, Nox2, and Nox4 was significantly increased, suggesting that ROS can independently activate pro-fibrotic and matrix remodelling gene expression patterns. Furthermore, treatment of mouse mitral valve interstitial cells with cell permeable antioxidants attenuated TGF-β1-induced pro-fibrotic and matrix remodelling gene expression in vitro.

Conclusion: Activation of canonical TGF-β signalling is a major contributor to fibrosis and matrix remodelling in MMVD, and is amplified by increases in oxidative stress. Treatments aimed at reducing TGF-β activation and oxidative stress in early MMVD may slow progression of MMVD.

Keywords: Antioxidants; Cardiovascular surgery; Mitral valve; Regurgitation; Valves.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TGF-β1 expression, levels of canonical TGF-β1 signalling molecules, and SMAD target gene expression in non-myxomatous and myxomatous human mitral valve tissue. (A) TGF-β1 expression is significantly increased in MMVD (qRT–PCR, n= 24 non-myxomatous valves, n= 24 myxomatous valves). (B–E) Western blots showing SMAD2/3 phosphorylation (B and D) and subsequent quantitation using densitometry (C and E). Note that SMAD2/3 phosphorylation—indicative of canonical TGF-β1 signalling—is significantly increased in MMVD (n= 5 non-myxomatous valves, n= 5 myxomatous valves). (F–H) Changes in CTGF, MMP2, and MMP9 in MMVD. Note that CTGF (F) and MMP2 (G) are markedly increased in MMVD (qRT–PCR, n= 24 non-myxomatous valves, n= 24 myxomatous valves). (I and J) Changes in expression of the intracellular E3 ubiquitin ligases SMURF1 and SMURF2, which are key negative regulators of canonical Smad signalling. Note that both SMURF1 and SMURF2 are markedly increased in human MMVD (n= 24 non-myxomatous valves, n= 24 myxomatous valves). *P < 0.05 in all figures.
Figure 2
Figure 2
ROS and pro/antioxidant gene expression in non-myxomatous and myxomatous human mitral valves. (A and B) Micrographs and quantitation of dihydroethidium staining in non-myxomatous and myxomatous human mitral valves. Note that ROS are significantly increased in valve tissue from patients with MMVD (n= 5 non-myxomatous valves, n= 5 myxomatous valves). (C–F) Expression of pro- and antioxidant genes in non-myxomatous and myxomatous human mitral valve tissue. Expression of Nox2 (C), Nox4 (D), and SOD1 (E) is significantly increased in myxomatous tissue. (F–H) Expression of other SOD isoforms (SOD2 and SOD3) and catalase was relatively unchanged (n= 24 non-myxomatous valves, n= 24 myxomatous valves for panels (C)(F). *P < 0.05 in all figures.
Figure 3
Figure 3
TGF-β1 mRNA expression and p-SMAD2/3 levels in mitral valves from SOD1 knockout mice compared with wild-type littermates. (A) TGF-β1 expression was unaltered in SOD1-deficient mitral valves (n= 9 wild-type valves, n= 13 knockout valves). (B–E) Immunoblots showing SMAD2/3 phosphorylation (B and D) and subsequent quantitation using densitometry (C and E). Note that similar to TGF-β1 expression, SMAD2/3 phosphorylation is not changed in mitral valves with SOD1 deficiency (n= 4 wild-type valves, n= 4 knockout valves). (F–H) Pro-fibrotic and matrix remodelling gene expression in mitral valves from wild-type and SOD1-deficient mice. Note that CTGF and MMP-2 are significantly increased in SOD1 knockout mice (n= 9 wild-type valves, n= 13 knockout valves). *P < 0.05 in all figures.
Figure 4
Figure 4
ROS and pro-oxidative gene expression in wild-type and SOD1-deficient mice mitral valves. (A and B) Micrographs and quantitation of dihydroethidium staining in wild-type and SOD1-deficient mitral valves. Note that ROS are significantly increased in valve tissue from mice lacking two copies of SOD1 (n= 4 wild-type valves, n= 4 knockout valves). (C and D) Pro-oxidative gene expression in mitral valves from wild-type and SOD1-deficient mice. Note that both Nox 2 and 4 are significantly increased in SOD1-deficient mice (n= 9 wild-type valves, n= 13 knockout valves). *P < 0.05 in all figures.
Figure 5
Figure 5
Effects of reducing oxidative stress on TGF-β1-induced gene expression (10 ng/mL TGF-β1 for 24 h) in mMVICs in vitro. (A–E) Effects of antioxidant treatment on induction of TGF-β1 signalling molecules and target genes related to myofibroblast activation, fibrosis, and matrix remodelling. Note that PEG-SOD (200 U/mL) tends to reduce SMAD phosphorylation levels and TGF-β1-induced myofibroblast activation (SM-α-actin) and CTGF expression, and abrogates TGF-β1-induced MMP-2 expression. (G and H) Regulation of anti/pro-oxidant enzyme expression in TGF-β1-treated mMVICs. Note that SOD1 is relatively unchanged and Nox4 is significantly increased in mMVICs after treatment with TGF-β1, whereas Nox2 is significantly reduced by TGF-β1. Furthermore, induction of Nox4 is relatively unaffected by treatment with PEG-SOD, whereas TGF-β1-induced suppression of Nox2 is eliminated by PEG-SOD. (I and J) Regulation of endogenous inhibitors of canonical TGF-β1 signalling by oxidative stress. Note that increases in SMURF1 and SMURF2 expression with TGF-β1 treatment were attenuated (or no longer significant) following treatment with PEG-SOD (n= 5 cell lines in each condition). *P < 0.05 for all figures.

Similar articles

Cited by

References

    1. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341:1–7. doi:10.1056/NEJM199907013410101. - DOI - PubMed
    1. Freed LA, Benjamin EJ, Levy D, Larson MG, Evans JC, Fuller DL, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol. 2002;40:1298–1304. doi:10.1016/S0735-1097(02)02161-7. - DOI - PubMed
    1. Li C, Gotlieb AI. Transforming growth factor-beta regulates the growth of valve interstitial cells in vitro. Am J Pathol. 2011;179:1746–1755. doi:10.1016/j.ajpath.2011.06.007. - DOI - PMC - PubMed
    1. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103–111. doi:10.1083/jcb.122.1.103. - DOI - PMC - PubMed
    1. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst. 2000;1:342–352. doi:10.3317/jraas.2000.064. - DOI - PubMed

Publication types

MeSH terms

Substances